Jobs
-
DDL 2017 drew 750 delegates, a record number, to the Edinburgh International Conference Centre. Topics that received sustained attention over the course of the 3-day meeting included the use of modeling techniques, development of inhaled… Read more . . .
-
Medical Developments International (MVP) has announced that the Decentralized Procedure for its Penthrox methoxyflurane inhaler marketing application has been completed, and the inhaler has been approved in an additional 22 countries. Penthrox has been available… Read more . . .
-
Glenmark Pharmaceuticals has announced that a 52-week Phase 3 trial of its Ryaltris mometasone furoate/olopatadine hydrochloride nasal spray for the treatment of perennial allergic rhinitis (PAR) met its primary and secondary endpoints. The company said… Read more . . .
-
Cambustion presented its Aerodynamic Aerosol Classifier (AAC), a monodisperse aerosol generation system, to a pharmaceutical audience for the first time at DDL 2017, the company said. According to the company, the AAC, which does not… Read more . . .
-
Insys Therapeutics has announced the initiation of a Phase 1 proof-of-concept study to determine whether an epinephrine nasal spray for the treatment of anaphylaxis is bioequivalent to intramuscular injection of epinephrine. The trial will compare… Read more . . .
-
Mucodel Pharma has announced that a PK study of its intranasal naloxone met its endpoints and showed that the formulation based on its Co-Gel technology delivered the dose of naloxone faster than both an intranasal… Read more . . .
-
Acorda Therapeutics said that it has resubmitted an NDA for its Inbrija levodopa DPI for the treatment of OFF periods in Parkinson’s disease patients. The company originally submitted the 505(b)(2) application in June 2017, and… Read more . . .
-
Aerogen Pharma and Lyomark Pharma have announced a partnership for development and commercialization of AP-002, a nasally-inhaled surfactant based on Lyomark’s Alveofact bovine lung surfactant for the treatment of respiratory distress syndrome (RDS) in pre-term… Read more . . .
-
Sunovion’s NDA for Lonhala Magnair glycopyrrolate inhalation solution (formerly known as SUN-101/eFlow) has been approved by the FDA for the treatment of COPD, the company said. A US launch is planned in early 2018. In… Read more . . .
-
Dance Biopharm announced that it has signed an agreement with Phillips-Medisize for development of a connected version of Dance’s Dance 501 insulin soft mist inhaler device. According to the announcement, Phillips-Medisize has already worked on… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK